Panu Jaakkola

Panu Jaakkola

Auto-generated profile, based on publicly available information

Panu Jaakkola

Department of Oncology and Radiotherapy, FICAN West Cancer Centre University of Turku and Turku University Hospital Turku Finland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2001 in Science
Verified
Journal Article
Closed access
PDF file
PJPanu Jaakkola
Panu Jaakkola
DMDavid R. Mole
David R. Mole
YTYa-Min Tian
Ya-Min Tian
MWMichael I. Wilson
Michael I. Wilson
JGJanine Gielbert
Janine Gielbert
PRPeter J. Ratcliffe
Peter J. Ratcliffe
Hypoxia-inducible factor (HIF) is a transcriptional complex that plays a central role in the regulation of gene expression by oxygen. In oxygenated and iron replete cells, HIF-α subunits are rapidly destroyed by a mechanism that involves ubiquitylation by the von Hippel–Lindau tumor suppressor (pVHL) E3 ligase complex. This process is suppressed by hypoxia and iron chelation, allowing transcriptional activation. Here we show that the interaction between human pVHL and a specific domain of the HIF-1α subunit is regulated through hydroxylation of a proline residue (HIF-1α P564) by an enzyme we have termed HIF-α prolyl-hydroxylase (HIF-PH). An absolute requirement for dioxygen as a cosubstrate and iron as cofactor suggests that HIF-PH functions directly as a cellular oxygen sensor.

1 October 2001 in Cell
Verified
Journal Article
Closed access
AEAndrew C.R. Epstein
Andrew C.R. Epstein
JGJonathan Gleadle
Jonathan Gleadle
LMLuke A. McNeill
Luke A. McNeill
KHKirsty S. Hewitson
Kirsty S. Hewitson
JOJohn O'Rourke
John O'Rourke
PRPeter J. Ratcliffe
Peter J. Ratcliffe

1 August 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MCMatthew E. Cockman
Matthew E. Cockman
NMNorma Masson
Norma Masson
DMDavid R. Mole
David R. Mole
PJPanu Jaakkola
Panu Jaakkola
GCGin-Wen Chang
Gin-Wen Chang
PMPatrick H. Maxwell
Patrick H. Maxwell
The von Hippel-Lindau tumor suppressor protein (pVHL) has emerged as a key factor in cellular responses to oxygen availability, being required for the oxygen-dependent proteolysis of α subunits of hypoxia inducible factor-1 (HIF). Mutations in VHL cause a hereditary cancer syndrome associated with dysregulated angiogenesis, and up-regulation of hypoxia inducible genes. Here we investigate the mechanisms underlying these processes and show that extracts from VHL-deficient renal carcinoma cells have a defect in HIF-α ubiquitylation activity which is complemented by exogenous pVHL. This defect was specific for HIF-α among a range of substrates tested. Furthermore, HIF-α subunits were the only pVHL-associated proteasomal substrates identified by comparison of metabolically labeled anti-pVHL immunoprecipitates from proteosomally inhibited cells and normal cells. Analysis of pVHL/HIF-α interactions defined short sequences of conserved residues within the internal transactivation domains of HIF-α molecules sufficient for recognition by pVHL. In contrast, while full-length pVHL and the p19 variant interact with HIF-α, the association was abrogated by further N-terminal and C-terminal truncations. The interaction was also disrupted by tumor-associated mutations in the β-domain of pVHL and loss of interaction was associated with defective HIF-α ubiquitylation and regulation, defining a mechanism by which these mutations generate a constitutively hypoxic pattern of gene expression promoting angiogenesis. The findings indicate that pVHL regulates HIF-α proteolysis by acting as the recognition component of a ubiquitin ligase complex, and support a model in which its β domain interacts with short recognition sequences in HIF-α subunits.

27 July 2004 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
JMJan H. Marxsen
Jan H. Marxsen
PSPetra Stengel
Petra Stengel
KDKathrin Doege
Kathrin Doege
PHPekka Heikkinen
Pekka Heikkinen
TJTerhi Jokilehto
Terhi Jokilehto
EMEric Metzen
Eric Metzen
An important regulator involved in oxygen-dependent gene expression is the transcription factor HIF (hypoxia-inducible factor), which is composed of an oxygen-sensitive α-subunit (HIF-1α or HIF-2α) and a constitutively expressed β-subunit. In normoxia, HIF-1α is destabilized by post-translational hydroxylation of Pro-564 and Pro-402 by a family of oxygen-sensitive dioxygenases. The three HIF-modifying human enzymes have been termed prolyl hydroxylase domain containing proteins (PHD1, PHD2 and PHD3). Prolyl hydroxylation leads to pVHL (von-Hippel-Lindau protein)-dependent ubiquitination and rapid proteasomal degradation of HIF-1α. In the present study, we report that human PHD2 and PHD3 are induced by hypoxia in primary and transformed cell lines. In the human osteosarcoma cell line, U2OS, selective suppression of HIF-1α expression by RNA interference resulted in a complete loss of hypoxic induction of PHD2 and PHD3. Induction of PHD2 by hypoxia was lost in pVHL-deficient RCC4 cells. These results suggest that hypoxic induction of PHD2 and PHD3 is critically dependent on HIF-α. Using a VHL capture assay, we demonstrate that HIF-α prolyl-4-hydroxylase capacity of cytoplasmic and nuclear protein extracts was enhanced by prolonged exposure to hypoxia. Degradation of HIF-1α after reoxygenation was accelerated, which demonstrates functional relevance of the present results. We propose a direct, negative regulatory mechanism, which limits accumulation of HIF-1α in hypoxia and leads to accelerated degradation on reoxygenation after long-term hypoxia.

20 October 2008 in Oncogene
Verified
Journal Article
Closed access
JPJ-P Pursiheimo
J-P Pursiheimo
KRK Rantanen
K Rantanen
PHP T Heikkinen
P T Heikkinen
TJTerje Johansen
Terje Johansen
PJP M Jaakkola
P M Jaakkola

5 March 2007 in Oncogene
Verified
Journal Article
Open access
PDF file
MJM R Junttila
M R Junttila
RAR Ala-Aho
R Ala-Aho
TJT Jokilehto
T Jokilehto
JPJuha Peltonen
Juha Peltonen
MKM Kallajoki
M Kallajoki
Veli-Matti KähäriVeli-Matti Kähäri
Veli-Matti Kähäri
Recent studies indicate that the specificity of p38 mitogen-activated protein kinase (MAPK)-mediated cellular stress responses is determined by the expression pattern of the distinct p38 isoforms. Here, we have analysed the function of distinct p38 isoforms in the growth and invasion of head and neck squamous cell carcinomas (HNSCCs). Activation of p38 MAPK by arsenite resulted in inactivation of the ERK1,2 signaling pathway by dephosphorylation of MEK1,2 in primary human epidermal keratinocytes (HEKs), whereas in HNSCC cells this p38-mediated inhibition of the ERK1,2 pathway was absent. Quantitation of p38 pathway component mRNA expression in HNSCC cell lines (n=42) compared to HEKs (n=8) revealed that p38α and p38δ isoforms are predominantly expressed in both cell types and that MKK3 is the primary upstream activator expressed. Inhibition of endogenous p38α or p38δ activity by adenoviral delivery of corresponding dominant-negative p38 isoforms potently reduced MMP-13 and MMP-1 expressions, and suppressed the invasion of HNSCC cells through collagen. Dominant-negative p38α and p38δ inhibited squamous cell carcinoma (SCC) cell proliferation and inhibition of p38α activity also compromised survival of SCC cells. p38α and p38δ were predominantly expressed in HNSCCs (n=24) and nonneoplastic epithelium in vivo (n=6), with MKK3 being the primary upstream activator. Activation and expression of p38α and p38δ by tumor cells was detected in HNSCCs in vivo (n=16). Adenoviral expression of dominant-negative p38α or p38δ in cutaneous SCC cells potently inhibited their implantation in skin of severe combined immunodeficiency mice and growth of xenografts in vivo. Our results indicate that p38α and p38δ specifically promote the malignant phenotype of SCC cells by regulating cell survival, proliferation and invasion, suggesting these p38 MAPK isoforms as potential therapeutic targets in HNSCCs.